NBIX vs SUPN · P/E 45, rev $1.77B vs rev $426.8M
Neurocrine Biosciences Inc (NBIX) versus Supernus Pharmaceuticals Inc (SUPN) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Supernus Pharmaceuticals Inc (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SUPN revenue for 2026-06-30 was $426.8M. Net income was -$60.7M. SUPN currently screens at market cap $2.53B.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SUPN currently screens at market cap $2.53B.
Not investment advice. Open the NBIX and SUPN stock pages for the full models.
Not investment advice.